As of August 8, 2022, a total of five participants have been enrolled and the Bronx VA site continues to actively screen for new participants. Enrollment is continuing for this Phase 2, open-label study …
On July 28, 2022, the first participant was screened for the Phase 1 food effects study. This study is enrolling healthy volunteers and examines the effect of food on the bioavailability of MDMA. The …
Enrollment is continuing for our Phase 2, open-label study on the effectiveness of MDMA-assisted therapy in U.S. Veterans with chronic PTSD. This study is a comparative study that assesses two versus three …
On July 18, 2022, the first UK participant in our open-label Phase 2 study of MDMA-assisted therapy for PTSD was screened by the research team at the Institute of Psychiatry, Psychology & Neuroscience …
The FDA lifted the clinical hold from a MAPS-sponsored Phase 2 study of MDMA-assisted group therapy for the treatment of posttraumatic stress disorder among veterans at the VA Portland Health Care System …
On May 23, 2022, MAPS submitted a complete response to the U.S. Food and Drug Administration (FDA) addressing the concerns outlined in the continued partial clinical hold for MAPS-sponsored Study MPG1. …
Two new study sites are now enrolling for our MDMA-assisted therapy for PTSD Expanded Access program. The Pearl Institute in Waynesville, North Carolina, and Sage Integrative Health in Berkeley, California, …
The MAPS Europe team is delighted to announce that screening of participants for our open-label Phase 2 study of MDMA-assisted therapy for PTSD has begun at the Charité – Universitätsmedizin Berlin …
FOR IMMEDIATE RELEASE: May 9, 2022 The second, confirmatory Phase 3 trial of MDMA-assisted therapy for PTSD is now fully enrolled at 13 sites in the United States and Israel Completion of enrollment on …
As of early May, one subject has been treated and four subjects are being evaluated for treatment in the MAPS-sponsored Phase 2, open-label study of the comparative effectiveness of two vs. three MDMA-assisted …
As of April 15, 2022, the second and third participants are screening for treatment in the MAPS-sponsored Phase 2, open-label study of the comparative effectiveness of two vs. three MDMA-assisted therapy …
On April 15, 2022, the U.S. Food and Drug Administration (FDA) upheld a partial clinical hold on Study MPG1, preventing the study from being initiated. FDA did not address specific questions from the previous …
